Phase I/II trial investigating gedatolisib plus talazoparib in advanced triple negative or BRCA1/2 positive, HER2 negative breast cancers.

Saved in:
Bibliographic Details
Title: Phase I/II trial investigating gedatolisib plus talazoparib in advanced triple negative or BRCA1/2 positive, HER2 negative breast cancers.
Authors: Phadke S; Carver College of Medicine Department of Internal Medicine, University of Iowa, 200 Hawkins Drive, C21GH, Iowa City, IA, 52242, USA. Sneha-Phadke@uiowa.edu., Miller KD; Melvin and Bren Simon Comprehensive Cancer Center, Indiana University, Indianapolis, IN, USA., Shah A; Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA., Danciu OC; University of Illinois Cancer Center, Chicago, IL, USA., Chen Y; Department of Biostatistics and Medical Informatics, University of Wisconsin-Madison, Madison, WI, USA., Yu M; Department of Biostatistics, University of Michigan - Ann Arbor, Ann Arbor, MI, USA., Burkard ME; Carver College of Medicine Department of Internal Medicine, University of Iowa, 200 Hawkins Drive, C21GH, Iowa City, IA, 52242, USA., Wisinski KB; Carbone Cancer Center, University of Wisconsin-Madison, Madison, WI, USA.; Department of Medicine, University of Wisconsin-Madison, Madison, WI, USA.
Source: Breast cancer research and treatment [Breast Cancer Res Treat] 2025 Aug; Vol. 212 (3), pp. 521-530. Date of Electronic Publication: 2025 Jun 05.
Publication Type: Journal Article; Clinical Trial, Phase I; Clinical Trial, Phase II
Journal Info: Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 8111104 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7217 (Electronic) Linking ISSN: 01676806 NLM ISO Abbreviation: Breast Cancer Res Treat Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1573-7217
DOI:10.1007/s10549-025-07747-x